Angiographic findings, time course of regional and global left ventricular function, and clinical outcome in diabetic patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty.

[1]  C. Bauters,et al.  Patency of Percutaneous Transluminal Coronary Angioplasty Sites at 6-Month Angiographic Follow-Up: A Key Determinant of Survival in Diabetics After Coronary Balloon Angioplasty , 2001, Circulation.

[2]  R. Califf,et al.  Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: Lessons from the GUSTO-IIb Angioplasty Substudy , 2000 .

[3]  Shuyang Zhang,et al.  Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome. , 1999, American heart journal.

[4]  M. Leon,et al.  The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. , 1998, Journal of the American College of Cardiology.

[5]  J. Burchenal,et al.  Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. , 1998, Circulation.

[6]  T. Investigators.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[7]  E. Topol.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.

[8]  G. Stone,et al.  Primary stenting in acute myocardial infarction: the promise and the proof. , 1998, Circulation.

[9]  T. B. Investigators,et al.  Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) , 1997, Circulation.

[10]  R. Califf,et al.  Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction , 1997 .

[11]  R. Califf,et al.  Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. , 1996, Journal of the American College of Cardiology.

[12]  D. Faxon,et al.  Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. , 1996, Circulation.

[13]  J Col,et al.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.

[14]  A. Ceriello,et al.  Hemostatic and metabolic abnormalities in diabetes mellitus. The search for a link. , 1994, Haematologica.

[15]  J. Yudkin,et al.  Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? , 1993, British heart journal.

[16]  R. Califf,et al.  Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. , 1993, Journal of the American College of Cardiology.

[17]  E J Topol,et al.  Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. , 1990, Circulation.

[18]  G. Davı̀,et al.  Thromboxane biosynthesis and platelet function in type II diabetes mellitus. , 1990, The New England journal of medicine.

[19]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[20]  A. Jaffe,et al.  The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. , 1989, Journal of the American College of Cardiology.

[21]  F. Werf.  DISCREPANCIES BETWEEN THE EFFECTS OF CORONARY REPERFUSION ON SURVIVAL AND LEFT VENTRICULAR FUNCTION , 1989, The Lancet.

[22]  F. Feit,et al.  Determinants and protective potential of coronary arterial collaterals as assessed by an angioplasty model. , 1988, The American journal of cardiology.

[23]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[24]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[25]  L. Shapiro.  Echocardiographic features of impaired ventricular function in diabetes mellitus. , 1982, British heart journal.

[26]  D. Leaman,et al.  Diffuse Coronary Artery Disease in Diabetic Patients: Fact or Fiction? , 1978, Circulation.